{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-028620","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2025-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.183335+00:00","generated_at":"2026-05-16T12:28:38.781928+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Telomir Pharmaceuticals Approves CEO Compensation Adjustments Including Incentive Payouts and Salary Increase","bullets":["CEO Erez Aminov received a 2025 short-term incentive payout of $400,000 for operational and financing achievements.","Contingent milestone payout of $150,000 approved for future FDA acceptance of the Telomir-1 IND submission.","Transaction advisory award of 3% of the total TELI acquisition value granted for leadership in negotiating the potential acquisition.","Base salary adjusted to $500,000 effective January 1, 2026, based on external benchmarking."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-028620","json":"https://secwatch.observer/filing/0001493152-25-028620.json","markdown":"https://secwatch.observer/filing/0001493152-25-028620.md","text":"https://secwatch.observer/filing/0001493152-25-028620.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225028620/0001493152-25-028620-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225028620/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T12:28:38.781928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}